Based on this finding, we suggest that clinicians consider using genomic sequencing to identify the presence of variants in BRCA1/2 and other genes related to breast cancer, such as TP53, ATM, PTEN, and CDKN2A. This evidence concerns the gene CDKN2A and breast carcinoma.